MENU
+Compare
PCRX
Stock ticker: NASDAQ
AS OF
Apr 2, 04:01 PM (EDT)
Price
$24.84
Change
+$0.77 (+3.20%)
Capitalization
1.36B

PCRX Pacira BioSciences Forecast, Technical & Fundamental Analysis

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients... Show more

PCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for PCRX with price predictions
Apr 01, 2025

PCRX's RSI Oscillator climbs out of oversold territory

The RSI Indicator for PCRX moved out of oversold territory on March 13, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 36 similar instances when the indicator left oversold territory. In of the 36 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on March 21, 2025. You may want to consider a long position or call options on PCRX as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for PCRX just turned positive on March 20, 2025. Looking at past instances where PCRX's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PCRX advanced for three days, in of 303 cases, the price rose further within the following month. The odds of a continued upward trend are .

PCRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 58 cases where PCRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

PCRX moved below its 50-day moving average on April 01, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for PCRX crossed bearishly below the 50-day moving average on March 12, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PCRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for PCRX entered a downward trend on March 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PCRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.557) is normal, around the industry mean (60.617). P/E Ratio (32.742) is within average values for comparable stocks, (90.174). PCRX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.987). Dividend Yield (0.000) settles around the average of (0.122) among similar stocks. P/S Ratio (2.244) is also within normal values, averaging (20.094).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PCRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

View a ticker or compare two or three
PCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

PCRX is expected to report earnings to fall 36.78% to 57 cents per share on April 30

Pacira BioSciences PCRX Stock Earnings Reports
Q1'25
Est.
$0.58
Q4'24
Beat
by $0.12
Q3'24
Beat
by $0.09
Q2'24
Beat
by $0.20
Q1'24
Est.
$0.62
The last earnings report on February 27 showed earnings per share of 91 cents, beating the estimate of 79 cents. With 77.31K shares outstanding, the current market capitalization sits at 1.36B.
A.I. Advisor
published General Information

General Information

a manufacturer of injectable therapeutic products

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
5401 West Kennedy Boulevard
Phone
+1 813 553-6680
Employees
713
Web
https://www.pacira.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SUHIX44.98N/A
N/A
DWS Health and Wellness Inst
VHCIX132.48N/A
N/A
Vanguard Health Care Index Admiral
EQTKX15.16N/A
N/A
Shelton Equity Income Class K
PMPRX14.91N/A
N/A
Principal MidCap Value I R3
SGNFX44.08N/A
N/A
Sparrow Growth No-Load

PCRX and Stocks

Correlation & Price change

A.I.dvisor tells us that PCRX and ELAN have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PCRX and ELAN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PCRX
1D Price
Change %
PCRX100%
-3.14%
ELAN - PCRX
32%
Poorly correlated
-1.43%
TEVA - PCRX
28%
Poorly correlated
-0.52%
ACET - PCRX
27%
Poorly correlated
-2.65%
SNDL - PCRX
26%
Poorly correlated
+2.13%
NBIX - PCRX
25%
Poorly correlated
-3.25%
More